The Atrium C-Qur hernia mesh has been the subject of significant litigation, with a $66 million settlement reached in December 2021 to resolve over 3,000 lawsuits filed against the manufacturer. This settlement represents one of the larger hernia mesh litigation outcomes, though it’s important to understand that not all claims have been fully resolved—as of February 2026, 246 claims remain pending in the Atrium C-Qur Mesh Multidistrict Litigation (MDL), with at least 620 C-Qur claims still pending overall. A hernia mesh patient who experienced infection following C-Qur implantation, requiring additional surgery and months of recovery, represents the type of complication that drove these legal claims forward.
The C-Qur mesh was specifically marketed as an innovative hernia repair solution. Manufactured by Atrium Medical Corporation, the device consists of a polypropylene mesh coated with an Omega 3 gel derived from fish oil, intended to reduce tissue inflammation and promote healing. However, widespread reports of complications—including infection, mechanical failure, and tissue damage—led patients and their attorneys to file lawsuits claiming the device was defective and that Atrium failed to adequately warn about the risks. The company has since withdrawn C-Qur products and all surgical mesh from its business portfolio, further underscoring the severity of the issues involved.
Table of Contents
- What Specific Complications Have Been Reported With C-Qur Hernia Mesh?
- How Did the Litigation Develop and What Was the Settlement?
- What Are the Potential Compensation Amounts for C-Qur Mesh Claims?
- How Do You File a Claim and What Documentation Is Required?
- What Are the Critical Limitations and Risks in the Settlement Process?
- What Makes C-Qur Different From Other Hernia Meshes?
- Where Does Atrium Stand Today and What’s the Outlook for Remaining Claims?
- Conclusion
What Specific Complications Have Been Reported With C-Qur Hernia Mesh?
FDA adverse event data reveals a troubling pattern of complications among C-Qur mesh patients. Infection represented the largest category of reported problems, accounting for 42% of adverse events filed with the FDA. This means that roughly four in ten patients who experienced problems after C-Qur implantation suffered from surgical site infections, some of which required hospitalization and additional medical intervention. Mechanical failure of the mesh itself occurred in 18% of cases, where the device either degraded, separated, or failed to provide adequate hernia support, often necessitating revision surgery. Beyond infection and mechanical failure, the mesh caused a range of other serious complications.
Intestinal complications developed in 7% of cases, including perforations where the mesh penetrated through tissue, while 6% of patients experienced adhesions—abnormal tissue attachments that cause pain and can require further surgery. Additionally, reported cases included mesh migration (where the device moved from its intended location), organ perforation, and hernia recurrence requiring repeat surgery. These weren’t rare or isolated incidents; they represented a systematic pattern of device failure affecting hundreds of patients across the country. The severity of these complications underscores an important reality: hernia mesh complications often aren’t minor issues but instead require additional surgery, prolonged recovery, and ongoing medical care. A patient who develops an infection following C-Qur implantation may face weeks of antibiotic therapy, possible mesh removal, and delayed hernia repair—a far more complicated recovery than the initial hernia surgery. This cascade of additional medical problems is precisely what drove the litigation forward.
How Did the Litigation Develop and What Was the Settlement?
The Atrium C-Qur hernia mesh lawsuits were consolidated into a Multidistrict Litigation (MDL) in December 2016 in the U.S. District Court for the District of New Hampshire. An MDL consolidation occurs when multiple similar lawsuits against the same defendant are transferred to a single judge to streamline proceedings and avoid conflicting verdicts. In this case, the consolidation involved more than 3,000 individual lawsuits from patients across the country who claimed they had been harmed by the C-Qur mesh. Following nearly a decade of litigation, a settlement framework was established and formally approved by Judge Landya B. McCafferty in October 2024.
The settlement allocated $66 million to resolve the claims, with Milestone serving as the settlement fund administrator responsible for processing claims and distributing compensation. This approval represented a major milestone in the litigation, allowing the settlement process to move forward and providing an avenue for compensation to claimants who met the eligibility criteria. However, the settlement process remains incomplete. As of February 2026, 246 claims are still pending within the C-Qur Mesh MDL, and at least 620 additional C-Qur claims remain pending outside the MDL system. This means that while the settlement framework is in place, the actual distribution of compensation and final resolution of all cases continues. Claimants should be aware that pending claim status can affect both the timing of compensation and the ultimate amount received, particularly if settlements are distributed on a pro-rata basis when the total eligible claims exceed available settlement funds.
What Are the Potential Compensation Amounts for C-Qur Mesh Claims?
Settlement payouts in hernia mesh litigation vary significantly based on individual case circumstances. For C-Qur claims, the potential compensation range is estimated between $60,000 and $100,000 per settled case. This range reflects variations in the severity of complications, the extent of medical treatment required, lost wages, and other damages such as pain and suffering. A patient who experienced a simple infection requiring hospitalization and antibiotics might receive a different amount than a patient who underwent multiple revision surgeries due to mechanical failure and adhesion formation. Several factors influence where a claim falls within this range.
The type and severity of complications directly impact compensation—more serious injuries like organ perforation or multiple revision surgeries typically warrant higher settlements than uncomplicated infections. The amount of medical documentation supporting the claim also matters; clear records showing the C-Qur mesh was implanted, complications developed, and additional treatment was required strengthen a claim. Additionally, the timing of the claim affects potential recovery, since early settlements processed under the approved plan are more likely to receive full allocated amounts, while later claims may face pro-rata reductions if the settlement fund becomes exhausted. One important limitation to understand: these compensation estimates represent potential ranges based on settlement calculations, not guarantees. Actual individual payouts depend on the specific claim characteristics, the total number of valid claims submitted, and the settlement fund’s availability. A patient expecting a $100,000 payout should understand that their actual settlement could be lower, particularly if thousands of additional claims are validated and the fund must be divided among all eligible claimants.
How Do You File a Claim and What Documentation Is Required?
Filing a claim in the Atrium C-Qur mesh settlement requires specific documentation to establish eligibility and support your damages. Claimants must provide proof that they received a C-Qur hernia mesh implant, medical records documenting complications that developed following implantation, and evidence of the medical treatment required to address those complications. Hospitals and surgical centers where the initial hernia repair was performed maintain detailed surgical records, including implant documentation, that can be obtained through records requests. The settlement administrator, Milestone, manages the claim filing process and evaluates submissions against established eligibility criteria. This centralized process is designed to ensure consistency in claim evaluation, though it also means that claim review can take time.
Comparing this to hernia mesh litigation involving other manufacturers, the C-Qur settlement process is structured similarly—requiring documented evidence of the implant and subsequent complications—but the specific evaluation criteria and timelines may differ based on the settlement agreement’s terms. A practical consideration: the longer a claimant waits to file, the more challenging it may become to gather documentation. Medical records can be archived, facilities may have limited retention periods, and memories fade regarding exact dates and symptoms. Additionally, as the February 2026 status shows with 620+ pending claims, filing sooner rather than later positions your claim for earlier processing and evaluation. The claims evaluation process works through pending claims in queue, so early submission typically means earlier compensation.
What Are the Critical Limitations and Risks in the Settlement Process?
One significant limitation of hernia mesh settlements is that compensation is typically capped at the negotiated settlement fund amount, which doesn’t necessarily equal the total damages claimed. The $66 million Atrium settlement, while substantial, may be divided among several thousand validated claims. If the number of eligible claims significantly exceeds initial estimates, each claim receives a proportionally smaller payment through pro-rata distribution. This means a claimant might submit a claim expecting a certain amount based on damages calculation, only to receive a lower amount due to fund limitations. Another critical limitation involves the statute of limitations and claim deadlines. Settlement agreements establish strict deadlines for filing claims, typically measured in months or a few years from the settlement approval date.
Missing these deadlines means losing the right to compensation through the settlement, regardless of the strength of your case. A patient who experiences delayed complications years after implantation might not realize they have a claim until it’s too late to file within the settlement window. Additionally, claimants must often waive their right to sue Atrium separately in exchange for settlement compensation, meaning the settlement payout becomes their exclusive remedy. Patients should also understand that while the settlement framework is approved, individual claim outcomes aren’t guaranteed. Each claim undergoes evaluation to verify the implant was C-Qur, that complications are documented as related to the mesh, and that medical treatment records support the claim. Incomplete documentation, unclear cause-and-effect connections between the mesh and complications, or missed deadlines can result in claim denial or significantly reduced compensation. The complexity of medical causation in hernia mesh litigation means that not every patient with complications will successfully establish that their injuries were caused by the C-Qur device rather than other factors.
What Makes C-Qur Different From Other Hernia Meshes?
The C-Qur mesh’s distinctive feature was its Omega 3 gel coating derived from fish oil. Atrium marketed this coating as a mechanism to reduce inflammation and promote tissue integration with the implanted polypropylene mesh. The theoretical advantage was that the omega 3 coating would create a more biocompatible surface, reducing the immune system’s inflammatory response and potentially lowering complication rates. This positioning made C-Qur appear to be a more advanced, safer option compared to standard polypropylene meshes on the market.
However, the real-world performance didn’t match the marketing claims. The omega 3-coated approach apparently offered no protective benefit against infection or mechanical failure. In fact, the adverse event data shows complication rates comparable to or potentially worse than standard hernia meshes. Some litigation documents suggest that the coating may have actually contributed to complications by degrading over time, weakening the mesh structure, or altering tissue interaction in ways that promoted infection or adhesion formation. What was marketed as an innovation potentially became a liability.
Where Does Atrium Stand Today and What’s the Outlook for Remaining Claims?
Atrium Medical Corporation has completely withdrawn from the hernia mesh market, discontinuing not only C-Qur but all surgical mesh products. This withdrawal, following the settlement approval and ongoing litigation, suggests the company’s assessment that mesh manufacturing and liability exposure were untenable. The market departure provides no direct recourse for patients seeking continued product support or updated safety information, though it does eliminate ongoing sales of potentially problematic devices.
The remaining 620+ pending C-Qur claims as of February 2026 represent patients still working through the settlement evaluation process. These claims will eventually be processed, evaluated, and either approved for compensation or denied based on the settlement criteria. The settlement framework established in October 2024 remains the primary vehicle for compensation for C-Qur injuries, and claimants should prioritize submitting documentation to Milestone before any claim deadlines expire. The litigation chapter for C-Qur appears to be nearing its conclusion, making this an active window for affected patients to assert their claims.
Conclusion
The Atrium C-Qur hernia mesh complication litigation resulted in a $66 million settlement approved in October 2024, with compensation estimates ranging from $60,000 to $100,000 per claim depending on individual circumstances. The settlement was driven by documented complications affecting thousands of patients, including infection in 42% of adverse event reports, mechanical failure in 18%, and various other serious complications including intestinal damage, adhesions, and mesh migration. While the litigation framework is in place and claims are being processed, significant hurdles remain, including strict filing deadlines, documentation requirements, and the reality that pro-rata distribution may reduce individual payouts if the number of valid claims exceeds settlement fund availability.
If you received a C-Qur hernia mesh implant and experienced complications afterward, you may be eligible for compensation through the settlement. The critical steps are obtaining your medical records documenting the C-Qur implant and subsequent complications, contacting Milestone (the settlement administrator) to understand current claim deadlines, and submitting a complete claim with supporting documentation. With over 620 claims still pending as of February 2026, the settlement process remains active, but claimants should not delay in filing, as deadlines are firm and missing them eliminates access to compensation through this settlement.